Breadcrumb
A team of researchers at the RI-MUHC found two cellular pathways involved in TNBC tumour development...
New target for cystic fibrosis drug development: Ceramides
Bringing an innovative retinal gene therapy to clinic
Speakers: Dr. Jason M. Harley (Principal Investigator, Department of Surgery) and Dr. Elif Bilgic (Postdoctoral Fellow)
Success storiesThese are just a few examples of recent successes in business development at the RI-MUHC.Bringing a C-diff predictive...
Contact usWe welcome inquiries about Business Development Office services. Please email us: business.development@rimuhc.ca
Topic: Perspectives on a Life in Lipids
CLIP leadershipLiane Feldman, MDMedical Director, CLIPDr. Feldman is an investigator in the Injury Repair Recovery Program at the...
Work published in Nature Communications demonstrates a...
RI-MUHC researcher Ciriaco Piccirillo takes a leading role in Canada’s new Coronavirus Variants Rapid Response Network
In virtual (zoom) and face-to-face format in Sherbrooke and in the 3 participating centers.
The International Society of Hypertension honours the RI-MUHC...
Congratulations to Dr. Julia Valdemarin Burnier!
Topic: Developing a core outcome set for diabetes after pregnancy prevention trials: the COS-DAP project
The meaning of recovery goes beyond traditional clinical parameters
Experts at the CIM technology platforms are on site to support clinical research
Topic: Variance Modeling with the Mixed Effects Location Scale (MELS) Model for Ecological Momentary Assessment (EMA) Data
Topic: Empowering people living with Human Immunodeficiency Virus using mHealth
Changing our understanding of childhood brain tumours and how to treat them
Dr. Foster succeeds Dr. Michael Shevell effective September 1, 2021
Message from the Executive Director
About us
Honours and awards
Dialysis patients do not develop adequate antibodies with one dose of SARS-CoV-2 vaccine
Topic: Innovation in diagnostics with a focus on COVID-19